Atul Ltd 2012-13

Atul Ltd | Annual Report 2012-13 Products APIs, API Intermediates, Others Pharmaceuticals Business mainly comprises API intermediates and a few APIs. The products are used by customers belonging WR 3KDUPDFHXWLFDO LQGXVWU\ XQGHU ÀYH EURDG WKHUDSHXWLF categories, namely, cardiovascular, anti-depressant, anti- diabetic, anti-infective and anti-retroviral. The Business comprises about 38 products, relatively new to the portfolio RI SURGXFWV RI WKH &RPSDQ\ ,W LV QRW FXUUHQWO\ HQJDJHG LQ formulations of APIs. During the year, sales increased by 23% to ` 314 cr. Sales in India increased by 27% to ` FU ([SRUW VDOHV LQFUHDVHG E\ 18% to ` 143 cr and formed 46% of the total. Growth on account of volume was 11%. Sales from new products were ` 8 cr. Atul Bioscience, a 100% subsidiary company, focussed on production of advanced API intermediates , sales of which increased from ` 11 cr to ` 27 cr, almost wholly because of YROXPH LW XQGHUWRRN FDSDFLW\ H[SDQVLRQ LQ ERWK RI LWV SODQWV :RUOG PDUNHW IRU SKDUPDFHXWLFDOV LV HVWLPDWHG DW 86 EQ FRPSULVLQJ 86 EQ SUHVFULSWLRQ GUXJV DQG 86 EQ JHQHULF GUXJV DQG LV JURZLQJ DW DERXW ,QGLDQ SKDUPDFHXWLFDOV PDUNHW LV HVWLPDWHG DW 86 EQ LQFOXGLQJ VDOHV RXW RI ,QGLD DQG LV JURZLQJ DW DERXW 7KHUH DUH DURXQG PDMRU FRPSDQLHV ZKLFK GRPLQDWH WKH Pharmaceuticals ZRUOG PDUNHWSODFH LQ SUHVFULSWLRQ GUXJV VSDFH ZLWK VKDUH of about 67% and around 8 companies in generic drugs space with share of about 70%. 7KH PDLQ XVHU LQGXVWU\ QDPHO\ +HDOWKFDUH LV JURZLQJ ZHOO because of increasing awareness about diseases and health. The Company along with Atul Bioscience will participate in WKLV JURZWK E\ L ZLGHQLQJ LWV PDUNHW UHDFK LL LQFUHDVLQJ LWV PDQXIDFWXULQJ HIÀFLHQFLHV LLL JHQHUDWLQJ DQG DGGLQJ FDSDFLWLHV DQG LY LQWURGXFLQJ QHZ SURGXFWV ,W ZLOO DOVR IRUP long-term alliances with other companies. 3ULFHV RI PDQ\ SURGXFWV FRPH GRZQ VLJQLÀFDQWO\ LQ D VKRUW WLPH )OXFWXDWLRQV LQ IRUHLJQ H[FKDQJH ZLOO LPSDFW VDOHV realisations.